גליבק  100 מג Israel - Ibrani - Ministry of Health

גליבק 100 מג

novartis israel ltd - imatinib as mesylate - טבליות מצופות פילם - imatinib as mesylate 100 mg - imatinib - imatinib - glivec is indicated for the treatment of adult patients and children 3 years of age and above with ph+ chronic myeloid leukaemia (ph+ -cml) in chronic phase accelerated phase or blast crisis. glivec is also indicated for the treatment of adult patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). glivec is also indicated for the treament of : adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph + all as monotherapy. adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. adult patients with myelodyspiastic/myeloproliferative diseases (mds/mpd) associated with pdgfr ( platelet - derived growth factor receptor ) gene re- arrangements. adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic l

גליבק   400 מג Israel - Ibrani - Ministry of Health

גליבק 400 מג

novartis israel ltd - imatinib as mesylate - טבליות מצופות פילם - imatinib as mesylate 400 mg - imatinib - imatinib - glivec is indicated for the treatment of adult patients and children 3 years of age and above with ph+ chronic myeloid leukaemia (ph+ -cml) in chronic phase accelerated phase or blast crisis. glivec is also indicated for the treatment of adult patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). glivec is also indicated for the treament of : adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph + all as monotherapy. adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. adult patients with myelodyspiastic/myeloproliferative diseases (mds/mpd) associated with pdgfr ( platelet - derived growth factor receptor ) gene re- arrangements. adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic l

סיאנה Israel - Ibrani - Ministry of Health

סיאנה

pfizer pfe pharmaceuticals israel ltd - medroxyprogesterone acetate - תרחיף להזרקה - medroxyprogesterone acetate 104 mg / 0.65 ml - medroxyprogesterone - medroxyprogesterone - * sayana is indicated for long-term female contraception. each subcutaneous injection prevents ovulation and provides contraception for at least 13 weeks (+/- 1 week). however, it should be taken into consideration that the return to fertility (ovulation) may be delayed for up to one year .since loss of bone mineral density may occur in females of all ages who use sayana long-term, a risk/benefit assessment, which also takes into consideration the decrease in bone mineral density that occurs during pregnancy and/or lactation, should be considered.* use in adolescents (12-18 years)in adolescents, use of sayana is only indicated when other contraceptive methods are considered unsuitable or unacceptable, due to unknown long-term effects of bone loss associated with sayana during the critical period of bone accretion.sayana has not been studied in women under the age of 18 years but data is available for intramuscular medroxyprogesterone acetate in this population.

ריספרידקס 1 מג Israel - Ibrani - Ministry of Health

ריספרידקס 1 מג

dexcel pharma technologies ltd - risperidone - טבליה - risperidone 1 mg - risperidone - risperidone - risperidex is indicated for the management of schizophrenia and the manifestations of psychotic disorders. the antipsychotic efficacy of risperdone was established in short-term (6 to 8 weeks) controlled trials of schizophrenic inpatients. risperidex is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. risperidex is indicated for the treatment of psychotic manifestations of dementia. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years. risperidex is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated expansive or irritable mood inflated self-esteem decreased need for sleep pressured speech racing thoughts distract

ריספרידקס 2 מג Israel - Ibrani - Ministry of Health

ריספרידקס 2 מג

dexcel pharma technologies ltd - risperidone - קפליות - risperidone 2 mg - risperidone - risperidone - risperidex is indicated for the management of schizophrenia and the manifestations of psychotic disorders. the antipsychotic efficacy of risperdone was established in short-term (6 to 8 weeks) controlled trials of schizophrenic inpatients. risperidex is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. risperidex is indicated for the treatment of psychotic manifestations of dementia. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years. risperidex is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated expansive or irritable mood inflated self-esteem decreased need for sleep pressured speech racing thoughts distract

ריספרידקס 3 מג Israel - Ibrani - Ministry of Health

ריספרידקס 3 מג

dexcel pharma technologies ltd - risperidone - טבליה - risperidone 3 mg - risperidone - risperidone - risperidex is indicated for the management of schizophrenia and the manifestations of psychotic disorders. the antipsychotic efficacy of risperdone was established in short-term (6 to 8 weeks) controlled trials of schizophrenic inpatients. risperidex is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. risperidex is indicated for the treatment of psychotic manifestations of dementia. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years. risperidex is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated expansive or irritable mood inflated self-esteem decreased need for sleep pressured speech racing thoughts distract

ריספרידקס 4 מג Israel - Ibrani - Ministry of Health

ריספרידקס 4 מג

dexcel pharma technologies ltd - risperidone - קפליות - risperidone 4 mg - risperidone - risperidone - risperidex is indicated for the management of schizophrenia and the manifestations of psychotic disorders. the antipsychotic efficacy of risperdone was established in short-term (6 to 8 weeks) controlled trials of schizophrenic inpatients. risperidex is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. risperidex is indicated for the treatment of psychotic manifestations of dementia. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years. risperidex is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated expansive or irritable mood inflated self-esteem decreased need for sleep pressured speech racing thoughts distract

רקוויפ מודוטאב 2 מג Israel - Ibrani - Ministry of Health

רקוויפ מודוטאב 2 מג

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - טבליות מצופות פילם - שחרור ממושך - ropinirole as hydrochloride 2 mg - ropinirole - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

רקוויפ מודוטאב 8 מג Israel - Ibrani - Ministry of Health

רקוויפ מודוטאב 8 מג

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - טבליות מצופות פילם - שחרור ממושך - ropinirole as hydrochloride 8 mg - ropinirole - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

רקוויפ מודוטאב 4 מג Israel - Ibrani - Ministry of Health

רקוויפ מודוטאב 4 מג

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - טבליות מצופות פילם - שחרור ממושך - ropinirole as hydrochloride 4 mg - ropinirole - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.